Pharmacokinetics of Orally Administered Clonidine in Dogs Authors: Kevin Pflaum, Julia Albright, Sherry Cox, Joe Smith Published: 2026 ABSTRACT ABSTRACTClonidine is an α‐2 agonist shown to be both well tolerated and useful in the treatment of canine fear‐based disorders, although it is perceived to have a short duration of action. Clonidine is available in regular release and extended‐release formulations, but canine pharmacokinetic (PK) and pharmacodynamic (PD) data on any clonidine formulation are lacking. The aim of this study was to establish PK and PD parameters of regular release (RR) clonidine in dogs. Clonidine RR (n = 6) was orally administered at 0.05 mg/kg to laboratory beagles. Clonidine RR showed a maximum concentration (C max) 1.5–2 h after administration and declined to below the level of quantification over 4–8 h after administration with an elimination half‐life (T 1/2) of 0.65 h. Slight reductions in heart rate and increases in sedation scores were seen in all treatment groups. In conclusion, obtained data indicated a single dose of clonidine RR at 0.05 mg/kg was well tolerated with mild sedation and bradycardia and no other adverse effects in healthy dogs.Keywords: clonidine, dog, fear, pharmacodynamics, pharmacokinetics Introduction Fear‐based behavior problems such as noise phobias, separation distress and aggression are common in dogs (Ramos et al. 2020). Fear is a behavioral and physiologic response involving activation of the neuroendocrine and autonomic nervous systems. Catecholamine release from the sympathetic nervous system (SNS) can result in trembling, hypersalivation, and eliminations, in addition to cowering, escape attempts, or aggression. These responses may result in injury to people or pets, stress to the owner and poor welfare for the affected dog. Psychopharmacological treatments for fear‐related disorders typically target the adrenergic system and neurotransmitters that modulate the SNS (e.g., serotonin and gamma‐amino‐butyric acid [GABA]). Anxiolytic medications with rapid onset are the most effective in reducing the clinical signs associated with fear, though many dogs have chronic fear disorders, and long‐term use of many of these medications is less than ideal. The benzodiazepines targeting GABAA have a relatively fast onset of action and good overall efficacy (Crowell‐Davis et al. 2003). However, benzodiazepine use is limited by the potential for dependency and tolerance, adverse effects including disinhibition of aggression, paradoxical excitement, ataxia, hyperphagia, and concerns regarding its controlled‐drug status, such as risk of human diversion and misuse. Gabapentin and pregabalin in the α‐2‐δ ligand class of drugs appear to primarily target voltage‐sensitive calcium channels, slowing signal transduction and modulating neurotransmitter release. However, they have similar controlled‐drug designation in certain jurisdictions, dependency concerns, and may only be partially effective in reducing clinical signs (Stollar et al. 2022). Trazodone antagonizes the 5HT2A serotonin receptor creating sedation and some mild anxiolysis (Gruen and Sherman 2008), but not all data has supported its efficacy above placebo (Gruen et al. 2017). Alternative or adjunctive anxiolytic options are needed for those dogs demonstrating a poor response or adverse effects to the current first‐line therapies. The α‐2 agonists have shown promise in reducing fear, panic, and hypervigilance by targeting the noradrenergic system. Orotransmucosal dexmedetomidine is labeled for the treatment of canine noise sensitivities and is used extra‐label for other fear disorders (Korpivaara et al. 2017). Dexmedetomidine's short duration of action makes it impractical for maintenance use. Clonidine is another α‐2 agonist, labeled for use as an antihypertensive agent in humans, but is now more widely prescribed extra‐label in psychiatric medicine to reduce symptoms of hyperarousal and hypervigilance (Croxtall 2012). The use of clonidine for canine fear‐related disorders has also risen rapidly within the last decade. An open trial of 22 dogs prescribed clonidine (0.01–0.05 mg/kg q 12 h) demonstrated satisfactory reduction in clinical signs of various fear‐related behaviors according to the dog owners (Ogata and Dodman 2011). However, little empirical evidence on the pharmacokinetics and pharmacodynamics of clonidine in dogs exists (Xu et al. 2016). One pharmacokinetic study of clonidine in dogs has been published, and in that study of compounded clonidine and hydrochlorothiazide, another antihypertensive drug, the average half‐life of clonidine was 2 h at a dose of 225 μg per dog (Xu et al. 2016). Reported canine dose ranges for clonidine based on anecdotal evidence are 0.01–0.05 mg/kg PRN q 8 h (Denenberg 2021), and many clinicians perceive it to have an approximate 2‐h delay in onset and 4–6 h duration of effect post‐oral administration. As many fear‐producing stimuli are present in the environment longer than 6 h, pharmacokinetic data is needed to inform the optimal redosing frequency. To increase the duration of action and improve client compliance, clonidine extended release (ER) has become an appealing option, but the pharmacokinetics of clonidine ER is also unknown in dogs, making dose and frequency determination challenging. Some ER formulations of other medications marketed for humans have shown comparable extended‐release pharmacokinetics in veterinary species (Barnard et al. 2017). In this study we aim to establish a pharmacokinetic profile for single‐dose clonidine regular‐release (RR) and clonidine ER in dogs. Materials and Methods Animals: 8 laboratory beagles (4 spayed females, 4 neutered males) were included in the study. All subjects had complete physical exams performed by the investigators, and all were deemed healthy within 48 h of data collection. All procedures involving animals were reviewed and approved by the University of Tennessee Institutional Animal Care and Use Committee (IACUC Protocol # 2825‐0221), and ethics dictated US standards for the protection of animals used for scientific purposes were adhered to. Demographic information is detailed in Table 1. TABLE 1Demographic information for study beagles, including name, age (in years), weight (kg), and sex (female spayed FS or male neutered MN).BeagleAge (years)Weight (kg)SexElsa412.0FSPebbles19.9FSBarney111.4MNWilma112.6FSOlaf512.8MNPotato411.3FSLuna49.8FSFred114.1MN Demographic information for study beagles, including name, age (in years), weight (kg), and sex (female spayed FS or male neutered MN). The day of the study, fasted dogs had a peripheral line catheter (MILA Drum Long Line Catheter, MILA International, Florence, Kentucky) placed in a lateral saphenous vein under local anesthesia. The catheters were secured with tape and vet wrap and further protected with Elizabethan collar placement and constant monitoring of the dogs. Dogs were fasted for at least 12 h and received clonidine RR and ER formulations in crossover dosing events. Six dosing events involved administration of 0.05 mg/kg clonidine HCL RR tablets (clonidine HCL 0.1 mg, Trupharma LLC), and six dosing events involved administration of 0.05 mg/kg clonidine HCL ER tablets (clonidine HCL 0.1 mg ER, Ajanta Pharma USA Inc). Tablets were coated in a small amount of spray cheese product and voluntarily consumed by all the dogs. Sample Collection Blood samples (2 mL) were collected from the indwelling catheter prior to medication administration (0) and then at 15, 30, 45, 60, 75, 90 min and 2, 2.5, 3, 4, 6, 8 h. The sampling protocol included flushing 1 mL of 0.9% heparinized saline into the catheter and withdrawing 2 mL before collecting a 2 mL blood sample into a heparinized collection tube. The 2 mL saline‐blood solution was then returned to the dog via catheter. Blood was collected from a direct venipuncture of the jugular, saphenous, or cephalic vein in cases where the catheter became non‐patent. Samples were stored on ice until they were centrifuged. The separated plasma was stored at −80°C until High‐Performance Liquid Chromatography (HPLC) analysis was performed. Analytical Chemistry Analysis of clonidine in plasma samples was conducted using reverse phase high performance liquid chromatography method. The instrumentation used was a 2695 separations module, and a 2487 UV absorbance detector (Waters, Milford, MA). The compounds were separated on an XBridge C18 (4.6 × 150 mm, 5 μm) column. The mobile phase was an isocratic mixture of 0.2 mM potassium phosphate monobasic (pH 4.5) and acetonitrile (87:13). The flow rate was 0.9 mL/min and absorbance was measured at 254 nm. Clonidine was extracted from plasma samples using a liquid–liquid extraction method. Samples that were previously frozen were thawed, vortex‐mixed, and 100 μL of plasma was transferred to a 13 × 100 mm screw top tube followed by 25 μL of trimethoprim (internal standard, 1 μg/mL) and 1 mL chloroform. The tubes were capped and vortexed for 60 s and then centrifuged for 20 min at 1000×g. The organic layer was transferred to a glass tube and evaporated to dryness with nitrogen gas. Samples were reconstituted in 200 μL of mobile phase and 100 μL was analyzed. Standard curves for the plasma analysis were prepared by fortifying untreated, pooled plasma with clonidine, which produced a linear concentration range of 5–1500 ng/mL. Average recovery for clonidine was 94% while the average recovery for the internal standard was 93%. The QC samples used for validation were 15, 350, and 750 ng/mL, and the intra and inter‐assay variability ranged from 1% to 10%. The lower limit of quantification was 5 ng/mL. Pharmacokinetic Analysis Total plasma concentration versus time data for clonidine in individual samples was used for pharmacokinetic in a non‐compartmental (statistical moments) moment approach with a commercial software (PKanalix, Monolix Suite 2023R1, Lixoft, France). Time versus concentration figures for clonidine in plasma were produced using a commercial software program (GraphPad Prism version 8.0, GraphPad Software, La Jolla CA USA). A linear/log trapezoidal rule was used to estimate the area under the time curves. Reported pharmacokinetic parameters for clonidine include: Maximum clonidine concentration after PO administration, C max; Maximum clonidine concentration after PO administration, C max; Slope of the elimination phase of clonidine λ z , computed by linear regression of the logarithmic concentration vs. time curve during the elimination phase; Slope of the elimination phase of clonidine λ z , computed by linear regression of the logarithmic concentration vs. time curve during the elimination phase; Clonidine plasma terminal half‐life, T 1/2 (λ z); Clonidine plasma terminal half‐life, T 1/2 (λ z); Time of maximum clonidine plasma concentration after PO administration, T max; Time of maximum clonidine plasma concentration after PO administration, T max; Area under clonidine concentration‐time curve to the last measurement, AUClast Area under clonidine concentration‐time curve to the last measurement, AUClast Area under clonidine concentration‐time curve extrapolated to infinity, AUCinf: Area under clonidine concentration‐time curve extrapolated to infinity, AUCinf: Extrapolated % of Area under the curve, %AUCext: Extrapolated % of Area under the curve, %AUCext: Area under the moments curve, AUMC; Area under the moments curve, AUMC; Clonidine mean residence time, MRTlast. Clonidine mean residence time, MRTlast. Summary statistics were performed on the individual PK parameters to determine the geometric mean and (min‐max) range. Harmonic mean was reported for elimination half‐life. Pharmacodynamic Analysis Heart rate and sedation scores for each subject within the same treatment group were averaged at every sample collection time point and plotted over time. Heart rate was calculated by counting heart beats obtained via auscultation over a 15 s time period and multiplying by 4 to calculate beats per minute (BPM). Sedation level was evaluated on a scale of −3 to +3 based on a global sedation scale developed for a previous canine α‐2 agonist study (Hopfensperger et al. 2013) (−3 = very excitable, −2 = somewhat excitable, −1 = subtle signs of excitation, 0 = normal, +1 = subtle signs of sedation, +2 = somewhat sedated, +3 = very sedated). Results Pharmacokinetics PK data were obtained from six RR dosing events and two ER dosing events. Although six ER administrations were performed, quantifiable plasma clonidine concentrations were detected following only two ER dosing events. No adverse effects were observed in any study animals. All dogs for which data were obtained had detectable plasma concentrations of clonidine until at least the 1.5 h time point after administration. The maximum concentration (C max) observed in the study dogs receiving regular release formulation (684 ng/mL) is greater than that in dogs receiving extended‐release (270 ng/mL). An effective anxiolytic concentration in dogs is not known. Concentration of clonidine regular release over time is displayed in Figure 1, and concentration of clonidine extended release over time compared against the mean concentration of regular release is displayed in Figure 2. PK data are provided in Tables 2 and 3. Time versus Concentration curve. Semilogarthmic plot of plasma clonidine concentrations after oral administration (dose: 0.05 mg/kg) of the regular release formulation in beagles (n = 6). Individual dog data is shown as individual lines with mean concentrations represented as solid circles with upward error bars. Pilot time vs. concentration curve. Semilogarthmic plot of mean plasma clonidine concentrations after oral administration (dose: 0.05 mg/kg) of the regular release formulation in beagles (n = 6) as well as preliminary data of extended‐release clonidine in 2 dogs (dose: 0.05 mg/kg). Individual dog data is shown as individual lines with mean concentrations represented as solid circles with upward error bars. TABLE 2Mean, minimum, and maximum values of pharmacokinetic data of regular‐release clonidine administered orally to 6 dogs at a dosage of 0.05 mg/kg.ParameterMean ± SD (n = 6)MedianMinMax C max (ng/mL)141.03 ± 2.98168.537684 T max (h)1.25 ± 1.351.50.751.5λz (1/h)0.84 ± 2.030.740.442.69 T 1/2 λ z (h)*0.65 (55.89)*0.990.261.59AUClast (h × ng)/mL160.65 ± 3.18247.8734.75573.88AUCinf (h × ng)/mL174.19 ± 3.14267.6736.98604.56AUC%extr (%)7.24 ± 1.466.764.8913.98AUMC327.28 ± 4.8651.3929.431414.93MRTlast (h)1.62 ± 1.541.930.742.3 Note: Data presented in geometric mean with the exception of T 1/2 λ z , which is presented as a harmonic mean (coefficient of variation)*.Abbreviations: AUC%extr, AUC extrapolated; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the curve measured to the last time point; AUMC, area under the moments curve; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; T 1/2 λ z (h), elimination half‐life; T max, time to maximum concentration; λz, elimination rate. Mean, minimum, and maximum values of pharmacokinetic data of regular‐release clonidine administered orally to 6 dogs at a dosage of 0.05 mg/kg. Note: Data presented in geometric mean with the exception of T 1/2 λ z , which is presented as a harmonic mean (coefficient of variation)*. Abbreviations: AUC%extr, AUC extrapolated; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the curve measured to the last time point; AUMC, area under the moments curve; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; T 1/2 λ z (h), elimination half‐life; T max, time to maximum concentration; λz, elimination rate. TABLE 3Individual pharmacokinetic data of extended‐release clonidine administered orally to 2 dogs at a dosage of 0.05 mg/kg.Parameter (unit)ER Dog 1ER Dog 2 C max (ng/mL)150270 T max (h)0.50.75λz (1/h)1.482.66 T 1/2 λ z (h)0.270.46AUClast (h × ng)/mL114.75150AUCinf (h × ng)/mL120.16152.26AUC%extr (%)4.51.48AUMC111.93117.37MRTlast (h)0.830.75Abbreviations: AUC%extr, AUC extrapolated; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the curve measured to the last time point; AUMC, area under the moments curve; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; T 1/2 λz (h), elimination half‐life; T max, time to maximum concentration; λ z , elimination rate. Individual pharmacokinetic data of extended‐release clonidine administered orally to 2 dogs at a dosage of 0.05 mg/kg. Abbreviations: AUC%extr, AUC extrapolated; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the curve measured to the last time point; AUMC, area under the moments curve; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; T 1/2 λz (h), elimination half‐life; T max, time to maximum concentration; λ z , elimination rate. Pharmacodynamics Transient reductions in heart rate (average reduction 71.67 BPM (40–96) for RR group, range 42–48 BMP for ER group) and increases in sedation score were observed in both treatment groups. All dogs recovered uneventfully. Only descriptive (summary) statistics are presented due to the small sample size, a lack of a control group for the PD values, and a lack of clinically significant differences between groups. The mean plasma concentration of clonidine RR and ER and mean sedation score over time is displayed in Figure 3, and mean plasma concentrations and mean HR over time in Figure 4. Given the limited ER sample size, presented data is intended to be descriptive and exploratory in nature. Concentration of clonidine (ng/mL) and sedation scores over time (h). Clonidine RR (n = 6), and clonidine ER (n = 2). Concentration of clonidine (ng/mL) and heart rate (BPM) data over time (h). Clonidine RR (n = 6) and clonidine ER (n = 2). Discussion Our preliminary PK data of dogs receiving a single oral dose of clonidine RR (n = 6) and clonidine ER (n = 2) at a dose of 0.05 mg/kg indicate the RR formulation closely matches anecdotal clinical observation: clonidine reached C max approximately 1.5–2 h after administration and dissipated over 4–8 h after administration with a T 1/2 λ z of 0.65 h. In comparison, clonidine ER reached C max 45–60 min after administration and dissipates over 2–3 h with a T 1/2 λ z of 0.37 h. Table 4 compares data from this study with the prior canine study and corresponding data reported in humans. TABLE 4Comparison of pharmacokinetic parameters for Clonidine RR and ER following administration of 0.05 mg/kg in the present study (Clonidine RR, n = 6; Clonidine ER, n = 2), with values reported in a previous canine study (0.225 mg/dog; Clonidine RR, n = 6) and in humans (0.1 mg/person; Clonidine RR, n = 15; Clonidine ER, n = 15). Subjects were fasted across comparison groups.SpeciesFormulation n Dose C max (ng/mL) T max (h) T 1/2 λz (h)AUCinf (h·ng/mL)MRTlast (h)ReferencesDogRR60.05 mg/kg141.0 ± 3.01.25 ± 1.350.65 ± 0.52269.22 ± 221.321.62 ± 1.54Present studyER a 20.05 mg/kg150–2700.50–0.750.27–0.46120.2–152.30.75–0.83Present studyRR60.225 mg/dog1.41 ± 0.350.95 ± 0.532.05 ± 1.224310.9 ± 1550.44.37 ± 2.43Xu et al. (2016)HumanRR150.1 mg/person0.44 ± 0.062.07 ± 0.5012.57 ± 3.117.31 ± 1.81NRFDA (2010)ER140.1 mg/person0.26 ± 0.036.50 ± 1.2312.65 ± 3.566.73 ± 1.65NRFDA (2010) Note: Pharmacokinetic parameters are presented as arithmetic mean ± SD.Abbreviations: AUCinf, area under the curve extrapolated to infinity; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; NR, not reported; T 1/2 λz (h), elimination half‐life; T max, time to maximum concentration. a ER dog data presented descriptively as ranges due to small sample size (n = 2). Comparison of pharmacokinetic parameters for Clonidine RR and ER following administration of 0.05 mg/kg in the present study (Clonidine RR, n = 6; Clonidine ER, n = 2), with values reported in a previous canine study (0.225 mg/dog; Clonidine RR, n = 6) and in humans (0.1 mg/person; Clonidine RR, n = 15; Clonidine ER, n = 15). Subjects were fasted across comparison groups. Note: Pharmacokinetic parameters are presented as arithmetic mean ± SD. Abbreviations: AUCinf, area under the curve extrapolated to infinity; C max, maximum concentration; MRTlast, mean residence time to the last timepoint; NR, not reported; T 1/2 λz (h), elimination half‐life; T max, time to maximum concentration. ER dog data presented descriptively as ranges due to small sample size (n = 2). Compared with the prior canine study, the difference in C max likely reflects the difference in the administered dose. Although the weights of the beagles in the prior study are not reported, a dose of 0.225 mg/dog roughly equates to a dose of 0.02 mg/kg in our beagle population. The markedly longer T 1/2 and AUC in our study likely reflect differences in the limits of detection and quantification, sampling time points, differences in the formulation of a compounded product vs. commercially made one, or outliers in a small sample size. In humans, clonidine ER has a lower C max and longer T max, reflected in a slower and steadier duration of action compared to RR. Thus, albeit in a limited data set, it was surprising that the ER formulation exhibits a similar C max, faster T max, and faster elimination half‐life compared with the RR formulation in our canine subjects. If a repeatable finding, the failure of the ER formulation to mimic the human pharmacokinetics may relate to disparate coatings or formulations of the specific drugs, or species differences in gastrointestinal anatomy and physiology including gastrointestinal length and gut transit time, enzyme/transporter abundance, protein binding, and cardiac output (Martinez et al. 2021). Clonidine is an antihypertensive medication that activates central α‐2 adrenergic receptors, resulting in inhibition of the SNS and lower peripheral vascular tone, renal vascular resistance, and decreased heart rate and overall blood pressure. In our dogs, initial reductions in heart rate and increases in sedation score, which recovered after roughly 3 h, were observed. These parameters were primarily collected to ensure the safety of the dogs during the study. Determining causation for these PD findings is limited due to small sample size and lack of a control group. High stress levels associated with the subject's transport from their housing to the treatment area and necessary handling/restraint for catheter placement led to elevated heart rate and arousal level at the initial sampling and observation time points. Likewise, reduction in handling and acclimation to the environment likely contributed to heavier sedation scores and reduction in heart rate at later time points regardless of medication. Yet, there is reason to consider the observations were due in part to clonidine administration, as sedation is a commonly reported side effect in humans and dose‐related decreases in heart rate and blood pressure have been reported (FDA 2010). Sedation is also a common clinical finding in dogs administered this dose. Further controlled canine studies are warranted to better confirm sedation and other behavioral effects in the canine population at prescribed doses. Other limitations of this study were the small sample size (particularly of the ER group) and homogeneity of the study population. Although six dogs received the ER formulation, measurable plasma clonidine concentrations were only detected in two dogs. The reason for this finding remains unclear and may reflect variability in absorption, formulation performance, or other methodological factors, as the dogs that did not achieve concentrations received clonidine ER from a different lot of the drug than the original 2 dogs. Consequently, interpretation of the ER data is limited and presented as a pilot. Future research should aim to collect both PK data for clonidine RR and ER over a larger, heterogeneous population to assess the validity of our findings. Pharmacodynamic data should be measured across a range of doses and compared against a control group. The impacts of fed versus fasted conditions, as well as the safety, pharmacokinetic, and pharmacodynamic effects of repeated dosing regimens, are clinically relevant and warrant further investigation. Conclusion In conclusion, both clonidine ER and RR formulations were well tolerated, producing only mild, transient decreases in heart rate and short‐lived sedation. However, the pharmacokinetic findings indicate that clonidine ER paradoxically provides a shorter duration of action without other benefits, such as faster onset or stronger sedation effects. Therefore, clonidine ER may not be useful for dogs in clinical practice and, based on the current findings, clinicians should continue to consider the RR formulation for treatment of canine fear and arousal disorders. The PK parameters identified here may help inform expectations regarding onset and duration of effect following single‐dose administration. However, further studies evaluating repeated dosing regimens, duration of clinical effects, and long‐term tolerability are warranted. Author Contributions Kevin Pflaum, Julia Albright, Sherry Cox, and Joe Smith developed study design. Kevin Pflaum and Julia Albright implemented sample collection. Sherry Cox and Joe Smith contributed to sample and data analysis. All authors contributed to the final manuscript. Funding Funding was generously provided by the University of Tennessee College of Veterinary Medicine Companion Animal Fund. Ethics Statement The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to and all procedures involving animals were reviewed and approved by the University of Tennessee Institutional Animal Care and Use Committee (IACUC Protocol # 2825‐0221). The authors confirm that they have adhered to the US standards for the protection of animals used for scientific purposes. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements This research was conducted with funding from the University of Tennessee College of Veterinary Medicine Companion Animal Fund. We would like to thank John Fang, Mitchell Rust, the research students, animal care staff, and dogs for their contributions to this study. Data Availability Statement The data generated and analyzed during this study are available from the corresponding author upon request. References Associated Data Data Availability Statement The data generated and analyzed during this study are available from the corresponding author upon request.